Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies

• Main Authors: Vassilis Genoud, Denis Migliorini
• Format: Article
• Language: English
• Published: MDPI AG 2021-03-01
• Series: International Journal of Molecular Sciences
• Subjects: glioblastoma; immunotherapy; clinical trials
• Online Access: https://www.mdpi.com/1422-0067/22/7/3493

Glioblastoma is the most frequent primary neoplasm of the central nervous system and still suffers from very poor therapeutic impact. No clear improvements over current standard of care have been made in the last decade. For other cancers, but also for brain metastasis, which harbors a very distinct biology from glioblastoma, immunotherapy has already proven its efficacy. Efforts have been pursued to allow glioblastoma patients to benefit from these new approaches, but the road is still long for broad application. Here, we aim to review key glioblastoma immune related characteristics, current immunotherapeutic strategies being explored, their potential caveats, and future directions.